Venture capital fund
Japanese venture group investing in regenerative medicine and stem cell venture companies.
Every published round Cell Innovation Partners Limited took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Cell Innovation Partners Limited has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Cell Innovation Partners Limited, as distinct from the investments it has made.
Companies Cell Innovation Partners Limited has backed that another company then bought. An exit for the holding, not a deal Cell Innovation Partners Limited did.
Stories naming Cell Innovation Partners Limited. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney-based tropoelastin biotech Elastagen agreed to an Allergan takeover offering US$95 million upfront plus contingent payments; the GBS Ventures-backed company previously drew MDF and federal grant funding.
Also GBS Ventures
Cell Innovation Partners invested A$1 million in Sydney biotech Elastagen within a second close of its A$14 million Series B, with AMOREPACIFIC Ventures, Korea Investment Partners and the Wellcome Trust also joining the round.